Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg

Contraception. 2006 Sep;74(3):234-8. doi: 10.1016/j.contraception.2006.03.008. Epub 2006 Jun 30.


Objective: This study aims to assess changes in bleeding patterns with the use of depot medroxyprogesterone acetate (DMPA) 104 mg/0.65 ml subcutaneous injection (DMPA-SC 104).

Study design: An analysis was conducted using data from two 1-year, noncomparative clinical trials (N=1787) and a 2-year randomized study comparing DMPA-SC 104 (N=266) with DMPA intramuscular injection (DMPA-IM). Bleeding was analyzed per 30-day interval by category and number of days. Analyses also were performed for age and body mass index (BMI) subgroups and for the percentages of women shifting from bleeding/spotting to amenorrhea after each injection.

Results: Each study showed decreased incidence of irregular bleeding and increased amenorrhea with continued use of DMPA-SC 104. Rates of amenorrhea at Month 12 (52-64% across studies) and Month 24 (71% in the 2-year trial) were comparable with those originally reported for DMPA-IM. Changes in bleeding patterns showed no consistent differences according to age or BMI. The percentages of subjects shifting from bleeding and/or spotting to amenorrhea increased with each subsequent injection.

Conclusion: Clinical data show that the incidence of amenorrhea increases over time with the use of DMPA-SC 104.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amenorrhea
  • Delayed-Action Preparations
  • Female
  • Humans
  • Injections, Intramuscular
  • Injections, Subcutaneous
  • Medroxyprogesterone Acetate / administration & dosage*
  • Menstrual Cycle / drug effects*
  • Uterine Hemorrhage


  • Delayed-Action Preparations
  • Medroxyprogesterone Acetate